Receive Discount Codes straight to your inbox!* (Conditions apply)

Discount code Subs form

By logging in or enrolling, you agree to have read our Privacy Policy and Ts & Cs, and to receive weekly email updates with new course content, materials, and valuable learning resources. Feel free to call or text us at 0432 894 232 for any assistance.

Chapter 1 · Cardiovascular Medicine · Lesson 2

Lipids and dyslipidaemia

Fellowship-level theory for the RACGP AKT and KFP, built on current Australian guidelines.

Next scheduled review: November 2027 Reading time ≈ 60 min
⚠ Guideline watch — read this first

Australia has no single national lipid guideline. Exam answers draw on three current sources: the 2023 Australian guideline for assessing and managing CVD risk (who to treat in primary prevention),1 the 2025 Heart Foundation/CSANZ acute coronary syndromes guideline (LDL-C target after ACS),3 and Therapeutic Guidelines plus the PBS Schedule (drug choice and subsidy).5,6

Older revision material still quotes the 2012 risk categories (>15% high risk) and an LDL-C target of <1.8 mmol/L after a coronary event. Both are superseded. In July 2026 the PBAC did not recommend bempedoic acid for PBS listing, so it is not a PBS option in Australia.8

What has changed recently
  • Jul 2026: PBAC did not recommend bempedoic acid for PBS listing.
  • 2025: Heart Foundation/CSANZ ACS guideline set the post-ACS LDL-C target at <1.4 mmol/L and ≥50% reduction.
  • 1 Nov 2024: ezetimibe (and statin combinations) became an unrestricted PBS benefit for 30-day supplies.
  • 2024: inclisiran PBS-listed (April); icosapent ethyl PBS-listed with TG and LDL-C criteria (October).
⚠ Studying from old notes?

Each statement below was standard teaching a few years ago. Decide whether it is still true before you tap.

After a heart attack, aim for an LDL-C below 1.8 mmol/L.
No longer true. The 2025 ACS guideline target is <1.4 mmol/L and at least a 50% fall from baseline. See 4.2.
Ezetimibe needs a PBS streamlined authority with criteria.
No longer true. Since 1 November 2024 a 30-day supply is an unrestricted benefit.
The PCSK9 options in Australia are evolocumab and alirocumab.
No longer true. Alirocumab is no longer available; inclisiran has been PBS-listed since April 2024.
A total cholesterol above 7.5 mmol/L automatically puts someone in the high-risk category.
No longer true. Since 2023 it means “treat and assess for FH”, but it is not a high-risk category on its own.

Cold-start check

Answer these five questions before you read the lesson. Getting some wrong is the point: attempting questions before studying helps you remember the answers afterwards, and your score tells you where to spend your time.

1. After an acute coronary syndrome, what is the current Australian LDL-C target?

<1.4 mmol/L and ≥50% reduction (2025 ACS guideline). The 1.8 target is superseded. Read 4.2 Secondary prevention: treat everyone, treat to target →

2. What is the PBS status of a 30-day supply of ezetimibe?

Unrestricted benefit since 1 November 2024. Read 6.2 Ezetimibe →

3. Which fibrate should never be combined with a statin?

Gemfibrozil markedly increases myopathy risk. Fenofibrate is the fibrate to use with a statin. Read 7. Statin safety and muscle symptoms →

4. How often does lipoprotein(a) usually need to be measured?

Once. Lp(a) is about 90% genetically determined and stable through life. Read 3.4 Lipoprotein(a) and other tests →

5. A fasting triglyceride of 12 mmol/L mainly puts the patient at immediate risk of which condition?

Acute pancreatitis — the main danger once fasting TG exceed 10 mmol/L. Read 9. Hypertriglyceridaemia and low HDL →

Your score: / 5

ScoreWhat to do
5 / 5Strong start. Skim the key takeaways, then go straight to the self-check questions.
3–4 / 5Read the sections linked from the questions you missed, then do the self-check.
0–2 / 5Work through the whole lesson. Your notes are probably out of date — check the old-notes box above.

Learning objectives

  1. Order and interpret a lipid profile, including non-fasting samples and non-HDL cholesterol.
  2. Exclude secondary causes before labelling primary dyslipidaemia.
  3. Decide who needs lipid-lowering therapy in primary and secondary prevention.
  4. Apply current LDL-C targets after ACS, stroke and in other established ASCVD.
  5. Choose, step up and monitor statins, ezetimibe and PCSK9-directed therapy within PBS rules.
  6. Manage statin-associated muscle symptoms without abandoning effective treatment.
  7. Recognise and act on familial hypercholesterolaemia and severe hypertriglyceridaemia.

How this is examined

  • AKT: statin intensity, percentage LDL-C reduction, LDL-C targets, PBS eligibility for ezetimibe and PCSK9 inhibitors, CK and ALT thresholds, drug interactions, DLCN categories, triglyceride thresholds for pancreatitis.
  • KFP: list of secondary-cause tests, the next step for a patient above target, statin rechallenge after muscle symptoms, what to tell relatives of a person with FH, pre-conception advice.
  • Common trap: treating a raised cholesterol before checking TSH, or answering from the old <1.8 mmol/L post-ACS target.
★ Study-priority stars

Every section carries a GP Institute study-priority rating. It is our editorial judgement, based on the RACGP curriculum, how heavily current Australian guidelines emphasise the topic, patient safety, recent changes, and the themes in published RACGP exam reports. It is not an official RACGP weighting, and any topic can be examined.

RatingWhat it means for your study
★★★★Must know. Core, frequently examined, safety-critical or recently changed. Know it cold, without notes.
★★★☆High yield. Commonly tested; know the thresholds, drugs and next steps.
★★☆☆Know the principles. Understand the reasoning; detailed numbers are less likely to be asked.
★☆☆☆Background. Read once for context.

1. Why it matters ★☆☆☆

Low-density lipoprotein cholesterol (LDL-C) is not just a marker of atherosclerotic cardiovascular disease (ASCVD); it is a cause. Genetic, epidemiological and randomised trial evidence all point the same way: the more LDL particles that enter the arterial wall, and the longer they stay there, the more plaque forms. Every 1 mmol/L reduction in LDL-C achieved with statins lowers the risk of major vascular events by about one-fifth, and the benefit continues to accrue at low LDL-C levels.13

Two ideas follow from this and drive the whole lesson. First, lifetime exposure matters: a person with familial hypercholesterolaemia (FH) reaches the cumulative LDL burden that causes coronary disease decades earlier than everyone else. Second, absolute benefit depends on absolute risk: the same statin gives a large benefit to someone after a myocardial infarction and a small one to a healthy 45-year-old. General practice decides who is treated, how hard, and whether they stay on treatment, which is where most of the population benefit is lost.

Core principle

Primary prevention: treat according to absolute CVD risk (Lesson 1), not according to a cholesterol number. Secondary prevention (established ASCVD): treat everyone, and treat to an LDL-C target.

2. Lipoproteins and classification ★★☆☆

Cholesterol and triglycerides are carried in the blood inside lipoproteins. Each atherogenic lipoprotein particle (LDL, VLDL remnants, IDL and lipoprotein(a)) carries one molecule of apolipoprotein B (apoB). That is why non-HDL cholesterol and apoB both capture the whole atherogenic burden, while LDL-C captures most of it.

Table 1. Lipoproteins that matter in practice
LipoproteinMain contentClinical significance
LDLCholesterol (apoB-100)Principal cause of atherosclerosis and main treatment target
VLDL and remnantsTriglyceride, some cholesterolAtherogenic; rise with obesity, insulin resistance, alcohol. Captured by non-HDL-C
ChylomicronsDietary triglycerideVery high levels (TG >10 mmol/L) cause acute pancreatitis and eruptive xanthomas
HDLCholesterol (apoA-I)Low HDL-C is a risk marker; drugs that raise HDL-C have not reduced events
Lipoprotein(a)LDL-like particle bound to apo(a)Genetically determined, independent causal risk factor; not lowered by statins

2.1 Primary and secondary dyslipidaemia ★★★☆

A practical classification asks two questions: which lipid is abnormal (LDL-C, triglycerides, or both), and is there a secondary cause? Primary (genetic) disorders range from monogenic FH to the far commoner polygenic hypercholesterolaemia and familial combined hyperlipidaemia (mixed pattern, variable between relatives). Secondary causes are common, frequently reversible and must be excluded first.

Table 2. Secondary causes of dyslipidaemia
CauseTypical patternTest
Hypothyroidism↑ LDL-C (often marked); raises statin myopathy riskTSH
Type 2 diabetes, insulin resistance, obesity↑ TG, ↓ HDL-C, small dense LDLHbA1c or fasting glucose; waist
Excess alcohol↑ TG (can be severe)History, GGT
Nephrotic syndrome↑ LDL-C, often very high; oedema, low albuminUrine ACR or dipstick, albumin
CKD↑ TG, ↓ HDL-CUEC/eGFR, uACR
Cholestatic liver disease↑ LDL-C (lipoprotein X)LFTs (ALP, GGT, bilirubin)
PregnancyPhysiological ↑ TC and TG, especially third trimesterHistory; do not screen in pregnancy
MedicinesCorticosteroids, oral oestrogen, retinoids, thiazides (high dose), some beta-blockers, antipsychotics (clozapine, olanzapine), ciclosporin, some antiretroviralsMedication review
Anorexia nervosa↑ LDL-CHistory, BMI
Exam pearl

Always check TSH before starting a statin for raised LDL-C. Untreated hypothyroidism both raises LDL-C and increases the risk of statin myopathy. Treat the thyroid first and repeat the lipids once the patient is euthyroid.

3. Testing and interpreting lipids ★★★☆

3.1 Who to test ★★★☆

Lipids are tested as part of absolute CVD risk assessment (ages 45–79; from 35 in diabetes; from 30 in First Nations people; Lesson 1), and earlier whenever there is a reason to suspect a problem.1,7

  • Family history of premature ASCVD or of FH or very high cholesterol.
  • Physical signs: tendon xanthomas, corneal arcus before 45, xanthelasma, eruptive xanthomas.
  • Diabetes, CKD, hypertension, smoking, obesity, inflammatory disease, HIV, severe mental illness, previous hypertensive disorder of pregnancy.
  • Children and adolescents with a parent who has FH or a known pathogenic variant (test between ages 5 and 10).10

3.2 Fasting or non-fasting? ★★☆☆

A non-fasting sample is appropriate for most screening and monitoring. Food has little effect on total cholesterol, HDL-C and non-HDL-C, and raises triglycerides only modestly. Ask for a fasting repeat when non-fasting triglycerides are above about 4.5 mmol/L (calculated LDL-C becomes unreliable), when severe hypertriglyceridaemia is suspected, or when monitoring triglyceride-lowering treatment.

Most Australian laboratories calculate LDL-C from TC, HDL-C and TG. The calculation underestimates LDL-C when triglycerides are high and when LDL-C is very low; non-HDL-C (TC minus HDL-C) is then the better measure. A non-HDL-C target is about 0.8 mmol/L above the corresponding LDL-C target.

Table 3. Reading a lipid profile (adults, mmol/L)
MeasureDesirable / usualFlags that change management
Total cholesterol<5.5>7.5: treat even at low absolute risk; screen for FH
LDL-C<3.5 (no CVD)≥5.0: consider FH (calculate DLCN score); ≥6.5 with no secondary cause: probable monogenic cause
Non-HDL-CLDL-C target + 0.8Use when TG raised or sample non-fasting
HDL-C≥1.0Low HDL-C → look for insulin resistance, smoking, inactivity
Triglycerides (fasting)<2.02.0–10: treat causes and overall risk; >10: pancreatitis risk, urgent management

Laboratory reference intervals vary. Treatment decisions follow absolute risk and the flags shown, not a single “normal range”.

3.3 Biological variation ★☆☆☆

LDL-C varies by about 5–10% between samples in the same person, and triglycerides by much more. Acute illness (infection, surgery, MI) lowers cholesterol for several weeks; a sample taken in the first 24 hours after an ACS still reflects baseline values. Repeat an unexpected result before a major decision such as an FH work-up.

3.4 Lipoprotein(a) and other tests ★★☆☆

Lipoprotein(a) [Lp(a)] concentration is about 90% genetically determined and stable through life, so it usually needs to be measured only once. The Australian Atherosclerosis Society recommends testing in people with premature ASCVD, people with FH or a family history of raised Lp(a) or premature ASCVD, and selected people at intermediate to high risk; universal screening is not recommended.11 Results should be reported in nmol/L. A high Lp(a) is a reason to treat other risk factors harder and to lower LDL-C more aggressively; there is no approved Lp(a)-specific drug in Australia yet.

Lp(a) testing is not funded by Medicare, so patients pay privately.12 ApoB measurement and coronary artery calcium scoring may help in selected people near a treatment threshold (Lesson 1).

4. Who to treat and LDL-C targets ★★★★

4.1 Primary prevention: follow absolute risk ★★★☆

The 2023 guideline links lipid-lowering decisions to the 5-year risk category from the Aus CVD Risk Calculator, after reclassification (Lesson 1).1,2

Table 4. Lipid-lowering decisions in primary prevention (2023 guideline)
CategoryLipid-lowering therapyNotes
HIGH ≥10% or clinically high riskPrescribe (usually a statin) together with BP-lowering therapy, after discussing benefits and harmsClinically high risk includes confirmed FH, eGFR <45, or uACR >25 (men) / >35 mg/mmol (women)
INTERMEDIATE 5 to <10%Consider, through shared decision-makingReclassification factors, Lp(a), CAC score and the person’s preferences help decide
LOW <5%Not routinely recommendedException: total cholesterol >7.5 mmol/L — treat and assess for FH

The 2023 guideline does not set a numerical LDL-C target for primary prevention. In practice, a moderate-intensity statin is usually started and the response is checked; a fall of 30–50% in LDL-C indicates the expected effect and adherence.

4.2 Secondary prevention: treat everyone, treat to target ★★★★

Everyone with established ASCVD — coronary heart disease, ischaemic stroke or TIA, or peripheral arterial disease — should be on a statin unless contraindicated, usually at high intensity. The current targets are below.

Table 5. LDL-C targets in established ASCVD
GroupCurrent Australian targetSource and notes
After acute coronary syndrome<1.4 mmol/L and ≥50% reduction from baseline; lower is better2025 Heart Foundation/CSANZ ACS guideline. Start high-intensity statin before discharge, whatever the baseline LDL-C3,4
Ischaemic stroke or TIA (atherosclerotic)<1.8 mmol/LStroke Foundation living guidelines (TST trial)9
Other stable ASCVD (chronic coronary disease, PAD)<1.8 mmol/L at minimum; <1.4 mmol/L for very high risk (recurrent events, polyvascular disease, diabetes with organ damage)Therapeutic Guidelines; international guidance (ESC) favours <1.45

↔ Swipe sideways to see the whole figure

LDL-C reduction needed to reach target: a baseline of 3.6 mmol/L falls to about 1.8 with a high-intensity statin, then about 1.4 with ezetimibe added, and below 1.0 with a PCSK9 inhibitor 01.02.03.03.6 LDL-C (mmol/L) Post-ACS target 1.4 1.8 3.61.81.40.8 Baseline High-intensity statin(≈50% fall) + ezetimibe(further ≈20%) + PCSK9 inhibitor(further ≈50–60%)
Figure 1. Illustrative LDL-C response to stepwise treatment after ACS, using typical average reductions. Individual responses vary; the target is <1.4 mmol/L and at least 50% below baseline.3,5
Exam pearl

After ACS, both parts of the target must be met. A patient whose LDL-C falls from 2.4 to 1.3 mmol/L is below 1.4 but has achieved only a 46% reduction, so treatment should still be intensified. Calculate the percentage fall in exam stems.

4.3 Algorithm: deciding on lipid-lowering therapy ★★★☆

Figure 2. Deciding who needs lipid-lowering therapy, combining the 2023 CVD risk guideline with secondary prevention and FH pathways.1,3

5. Lifestyle management ★★☆☆

Lifestyle changes are recommended for everyone, but their effect on LDL-C is modest compared with drugs. Their real value is in lowering overall risk: blood pressure, weight, glucose, triglycerides and smoking. For a person at high risk, lifestyle change runs alongside a statin, not instead of one.

Table 6. Lifestyle measures and approximate effect on lipids
MeasurePractical adviceApproximate effect
Replace saturated and trans fatsSwap butter, fatty meat, processed meat and baked goods for olive oil, nuts, seeds, fish and legumes; follow the Heart Foundation eating patternLDL-C ↓ 5–10%
Plant sterol-enriched foodsAbout 2 g sterols a day (e.g. enriched margarine or milk)LDL-C ↓ about 8–10%
Soluble fibreOats, barley, legumes, psylliumLDL-C ↓ about 5%
Weight loss5–10% of body weightTG ↓ markedly; HDL-C ↑; modest LDL-C fall
AlcoholNo more than 10 standard drinks a week and 4 on any day; abstain if TG severely raisedTG ↓, often dramatically
Physical activity150–300 min moderate activity a week plus muscle strengthening on 2 daysTG ↓, HDL-C ↑
Refined carbohydrate and sugarReduce sugary drinks and refined starchesTG ↓
Smoking cessationCounselling, Quitline, pharmacotherapyHDL-C ↑; large fall in CVD risk

Effect sizes are approximate and vary between individuals.

Fish oil supplements, red yeast rice and other over-the-counter products are not substitutes for evidence-based treatment. Red yeast rice contains monacolin K (chemically identical to lovastatin) in uncontrolled amounts and can cause the same adverse effects as a statin.

6. Lipid-lowering medicines ★★★★

6.1 Statins ★★★★

Statins inhibit HMG-CoA reductase, reduce hepatic cholesterol synthesis and up-regulate LDL receptors. They have the strongest outcome evidence of any lipid drug and are first-line in almost every situation. Intensity is defined by the expected LDL-C reduction.5,14

Table 7a. Statin intensity (daily doses)
IntensityExpected LDL-C fallDoses
High≥50%Atorvastatin 40–80 mg; rosuvastatin 20–40 mg
Moderate30–49%Atorvastatin 10–20 mg; rosuvastatin 5–10 mg; simvastatin 20–40 mg; pravastatin 40–80 mg
Low<30%Simvastatin 10 mg; pravastatin 10–20 mg; fluvastatin 20–40 mg

Doubling a statin dose lowers LDL-C by only about a further 6% (“rule of six”). Adding ezetimibe lowers it by about a further 20%, which is why ezetimibe is usually the next step once a statin is at a high-intensity dose.

Choosing a statin

  • Atorvastatin and rosuvastatin for most patients; long half-life, any time of day.
  • Rosuvastatin: reduce the dose in severe CKD and in people of East Asian ancestry (higher blood levels); start at 5 mg.
  • Pravastatin (and rosuvastatin, fluvastatin): fewer CYP3A4 interactions; useful with HIV protease inhibitors or ciclosporin (with dose limits).
  • Simvastatin: most CYP3A4 interactions; avoid 80 mg.

Adherence matters most

  • About half of patients stop a statin within a year of starting.
  • Explain the reason in absolute terms; address nocebo concerns about side effects.
  • Use a single daily dose, fixed-dose combinations and dose administration aids where needed.
  • Ask about adherence before escalating therapy.

6.2 Ezetimibe ★★★☆

Ezetimibe blocks intestinal cholesterol absorption (NPC1L1) and lowers LDL-C by about 20% on top of a statin, or 15–20% alone. Adding it to a statin after ACS produced a modest further reduction in events (IMPROVE-IT). It is well tolerated and can be started early, including before discharge after ACS.

What’s new — PBS, 1 November 2024

Ezetimibe and its fixed-dose combinations with statins no longer need a streamlined authority. 30-day supplies are an unrestricted benefit; 60-day supplies are restricted to people whose condition is stable.6 Older notes that say “check PBS criteria before prescribing ezetimibe” are out of date.

6.3 PCSK9-directed therapy ★★★☆

PCSK9 promotes breakdown of hepatic LDL receptors. Blocking it lowers LDL-C by about 50–60% on top of a statin and reduces Lp(a) by 20–30%.

  • Evolocumab: monoclonal antibody, subcutaneous injection every 2 weeks (or monthly). Reduced cardiovascular events in FOURIER.
  • Inclisiran: small interfering RNA that reduces PCSK9 production; subcutaneous injection by a health professional at day 1, 3 months, then every 6 months. PBS-listed since April 2024.15
  • Alirocumab is no longer available in Australia.4

PBS eligibility (non-familial, summarised): symptomatic ASCVD, LDL-C still above 1.8 mmol/L despite at least the maximum tolerated statin plus ezetimibe for an adequate period, with dietary therapy and exercise, plus at least one additional high-risk feature, such as diabetes with microalbuminuria, disease in two or more vascular territories, or recurrent events. Separate criteria apply to heterozygous and homozygous FH. Authority is required, and the wording changes, so check the current PBS Schedule.4,15

6.4 Other agents ★★☆☆

Table 7b. Non-statin lipid medicines
AgentMain useKey cautions
EzetimibeAdd-on to statin; statin intoleranceWell tolerated; avoid in moderate–severe hepatic impairment
Evolocumab, inclisiranVery high-risk ASCVD or FH above target on statin + ezetimibePBS authority criteria; injection-site reactions
FenofibrateSevere hypertriglyceridaemia (pancreatitis prevention); slows diabetic retinopathy progressionRaises creatinine (reversible); reduce dose or avoid in CKD; gallstones
GemfibrozilRarely usedDo not combine with a statin (marked myopathy risk)
Icosapent ethyl (purified EPA)Established CVD on a statin with LDL-C controlled (1.0–2.6 mmol/L) but fasting TG 1.7–5.6 mmol/L (PBS criteria, Oct 2024)4Increases AF and bleeding slightly; ordinary fish oil does not give the same benefit
Colestyramine (bile acid sequestrant)Additional LDL-C lowering; the option in pregnancyGI upset; raises TG; binds other drugs (separate doses by 1 hour before / 4 hours after)
Bempedoic acidStatin intolerance (international use)Not PBS-listed: PBAC did not recommend in July 20268

6.5 Algorithm: getting to target in established ASCVD ★★★☆

Figure 3. Stepwise LDL-C lowering in established ASCVD.3,5

6.6 Monitoring ★★★☆

Table 8. Monitoring lipid-lowering therapy
TestWhenAction
Lipid profile4–12 weeks after starting or changing therapy (4–8 weeks after ACS); then every 6–12 months in secondary prevention, at least yearly otherwiseCheck target and percentage fall; ask about adherence
ALTBaseline; repeat only if symptoms of liver diseaseALT >3 × ULN persistently: reduce dose or stop and investigate. Mild rises with fatty liver are not a reason to withhold a statin
CKNot routinely. Baseline only if high myopathy risk; check if muscle symptomsSee Table 9
HbA1cAs part of usual risk monitoringStatins slightly raise diabetes risk in predisposed people; the CVD benefit far outweighs this
UEC/eGFRBaseline; with fenofibrate, before and after startingAdjust rosuvastatin and fenofibrate doses

7. Statin safety and muscle symptoms ★★★★

True statin intolerance is uncommon. In blinded trials, muscle symptoms occur almost as often on placebo as on statin; much reported intolerance reflects the nocebo effect. Even so, symptoms are real to the patient and are the main reason people stop treatment. The goal is to keep the patient on an effective dose of some statin wherever possible.

Table 9. Statin-associated muscle symptoms (SAMS)
PresentationCKManagement
Myalgia (aches, usually symmetrical proximal; within weeks of starting or increasing)Normal or <4–5 × ULNLook for other causes (hypothyroidism, vitamin D deficiency, exercise, interacting drugs). If tolerable, continue; if not, withhold 2–4 weeks then rechallenge with a lower dose, a different statin or alternate-day dosing
Myopathy with marked CK rise>5 × ULN with symptomsStop the statin; check renal function; recheck CK; reintroduce cautiously once resolved, often a different statin at low dose
RhabdomyolysisUsually >10 × ULN, with myoglobinuria and raised creatinineStop statin; urgent hospital assessment (IV fluids, renal monitoring)
Asymptomatic raised CK<4–5 × ULNContinue statin; do not repeat routinely. Recent exercise often explains it
Immune-mediated necrotising myopathy (rare)Very high, persisting after stoppingProgressive weakness despite stopping; anti-HMGCR antibodies; refer to neurology or rheumatology
Figure 4. Managing statin-associated muscle symptoms.5,14
⚠ Safety alerts — interactions and myopathy risk
  • Strong CYP3A4 inhibitors (clarithromycin, erythromycin, itraconazole, ketoconazole, posaconazole, HIV protease inhibitors) sharply raise simvastatin and atorvastatin levels. Withhold simvastatin during a short course, or choose a non-interacting antibiotic.
  • Ciclosporin: avoid simvastatin; use low-dose pravastatin, fluvastatin or rosuvastatin with specialist advice.
  • Gemfibrozil + any statin: avoid. Fenofibrate is the fibrate to use with a statin.
  • Fusidic acid (systemic): stop the statin during treatment and for 7 days after (rhabdomyolysis).
  • Colchicine, amiodarone, verapamil, diltiazem: dose limits for simvastatin; monitor for symptoms.
  • Higher-risk patients: older age, low body weight, hypothyroidism, CKD, high alcohol intake, East Asian ancestry (rosuvastatin), multiple interacting drugs.

8. Familial hypercholesterolaemia ★★★☆

FH is an autosomal dominant disorder, usually caused by a pathogenic variant in LDLR, APOB or PCSK9. About 1 in 250 Australians has heterozygous FH, but only about 10% have been diagnosed.4,10 Untreated, it roughly triples the risk of premature coronary disease; men may present with MI in their 30s or 40s. Early treatment restores near-normal life expectancy.

8.1 When to suspect FH ★★★★

  • Adult LDL-C ≥5.0 mmol/L (or TC >7.5 mmol/L) without a secondary cause.
  • Personal or family history of premature coronary disease (men <55, women <60).
  • Tendon xanthomas (Achilles, extensor tendons of the hands) or corneal arcus before 45.
  • A relative with known FH or a pathogenic variant.
Table 10. Dutch Lipid Clinic Network (DLCN) score in adults (simplified)
CriterionPoints
Family historyFirst-degree relative with premature CHD or LDL-C >95th centile: 1. Relative with tendon xanthomas or arcus, or child with LDL-C >95th centile: 2
Personal historyPremature CHD: 2. Premature cerebral or peripheral vascular disease: 1
ExaminationTendon xanthomas: 6. Corneal arcus before 45: 4
Untreated LDL-C (mmol/L)≥8.5: 8 · 6.5–8.4: 5 · 5.0–6.4: 3 · 4.0–4.9: 1
Genetic testPathogenic variant: 8
InterpretationDefinite >8 · Probable 6–8 · Possible 3–5 · Unlikely <3

Use only the highest-scoring item in each group, and the untreated LDL-C. DLCN is not used in children; a child is likely to have FH if LDL-C is >5.0 mmol/L, or >4.0 mmol/L with a parent who has hypercholesterolaemia or premature CVD, or >3.5 mmol/L with a parent who carries a pathogenic variant.10

8.2 Genetic testing and cascade screening ★★★☆

Table 11. Medicare-funded FH genetic testing
TestWho can orderEligibility
Index case (MBS 73352)Specialist (not a GP)DLCN score ≥6; or LDL-C ≥6.5 mmol/L with no secondary cause; or LDL-C 5.0–6.5 mmol/L with signs of premature or accelerated atherosclerosis
Cascade testing (MBS 73353)GP can orderFirst- and second-degree relatives of a person with a known pathogenic variant, whatever their cholesterol level. Saliva or blood

A negative genetic test in the index case does not exclude FH: many people with a clinical diagnosis have no variant identified (polygenic or undiscovered causes), and they are treated the same way. Relatives of a clinically diagnosed person without a known variant are screened with lipid levels.10

8.3 Managing FH ★★☆☆

  • Treat as clinically high risk without using the calculator (the calculator underestimates risk in FH).
  • High-intensity statin plus ezetimibe is usually needed; aim to lower LDL-C by at least 50%, and lower still if ASCVD or other risk factors are present. PCSK9-directed therapy under PBS FH criteria if needed.
  • Refer to a lipid clinic for diagnosis, genetic testing, family coordination and children.
  • Children with FH: lifestyle from early childhood, and a statin from about 8–10 years under specialist guidance.
  • Women with FH: plan pregnancy (section 10).
  • Homozygous FH (LDL-C often >13 mmol/L, xanthomas in childhood) needs urgent specialist care.

9. Hypertriglyceridaemia and low HDL ★★★☆

Mild to moderate hypertriglyceridaemia (2–10 mmol/L) is very common and is usually driven by insulin resistance, obesity, diabetes and alcohol, on a polygenic background. Its importance is mainly as a marker of atherogenic remnant particles: management focuses on causes, overall CVD risk and non-HDL-C. Severe hypertriglyceridaemia (>10 mmol/L) is different: the main danger is acute pancreatitis.

Table 12. Hypertriglyceridaemia by severity (fasting TG, mmol/L)
LevelMain concernManagement
2.0–4.9CVD risk (remnants)Treat secondary causes and lifestyle; statin according to absolute risk; use non-HDL-C
5.0–9.9CVD risk; rising pancreatitis riskAs above, more intensively; consider fenofibrate if persistent; icosapent ethyl in established CVD meeting PBS criteria
≥10Acute pancreatitisRepeat fasting; stop alcohol completely; very low-fat diet; control glucose (insulin if very high); fenofibrate; review drugs (oral oestrogen, retinoids, antipsychotics). Specialist referral if >20 or recurrent
⚠ Red flags
  • TG >10 mmol/L with abdominal pain → same-day assessment for acute pancreatitis (lipase).
  • Eruptive xanthomas or lipaemia retinalis → severe hypertriglyceridaemia.
  • Lipaemic sample in a person with diabetes → check for very poor glycaemic control or DKA.
  • Untreated LDL-C ≥5.0 in an adult or >4.0 in a child, tendon xanthomas, arcus <45 → assess for FH.
  • Rapidly progressive muscle weakness on a statin, or dark urine → rhabdomyolysis or necrotising myopathy.

Low HDL-C is a marker of insulin resistance, smoking and inactivity. Treat the cause and the overall risk. Drugs that raise HDL-C (niacin, CETP inhibitors) have not reduced cardiovascular events and are not used for this purpose.

10. Special populations ★★★☆

Table 13. Special populations
GroupKey points
Pregnancy and pre-conceptionStatins are avoided in pregnancy (TGA category D) and while breastfeeding. Stop statins and ezetimibe before trying to conceive (usually 1–3 months beforehand) or as soon as pregnancy is confirmed. Colestyramine can be used if LDL-C lowering is needed. Women with FH or established ASCVD should have specialist pre-pregnancy advice. Do not test lipids during pregnancy (physiological rise)
DiabetesRisk assessed with the Aus CVD Risk Calculator diabetes equation (no automatic high-risk label); statins are most people’s first lipid drug. Fenofibrate may be added for diabetic retinopathy. Raised TG often improves with glycaemic control
CKDeGFR <45 or high uACR = clinically high risk. Statin or statin + ezetimibe in CKD not on dialysis (SHARP). Do not start statins in people on dialysis without other indications (no benefit in trials), but continue if already taking them. Reduce rosuvastatin dose in severe CKD; avoid or reduce fenofibrate
Older people (≥75)Continue statins in secondary prevention. In primary prevention the calculator is validated only to 79; individualise according to frailty, life expectancy and preferences. Deprescribing may be appropriate near the end of life
First Nations peopleRisk assessment from age 30; consider reclassifying upward; FH and CKD screening; culturally safe shared decision-making; Closing the Gap PBS co-payment measure reduces cost barriers16
People with HIVIncreased CVD risk; many antiretrovirals (especially boosted protease inhibitors) interact with simvastatin and atorvastatin — check an interaction resource
Severe mental illnessAntipsychotics raise TG and weight; higher CVD risk (reclassification factor); monitor lipids routinely
ChildrenTest when a parent has FH or a pathogenic variant, ideally between 5 and 10 years; refer for management

11. Old versus new guidance ★★★★

Revision notes, including some widely circulated summaries, still contain the guidance below. Exam questions are written to current guidance.

Table 14. Superseded versus current lipid guidance
TopicSupersededCurrent
Risk categoriesLow <10%, moderate 10–15%, high >15% (2012)Low <5%, intermediate 5 to <10%, high ≥10% (2023)
Automatic high riskDiabetes >60 or with microalbuminuria, BP ≥180/110, TC >7.5, First Nations >74Confirmed FH, eGFR <45, uACR >25 (men) / >35 mg/mmol (women) only. TC >7.5 means “treat”, not “high risk”
Reassessment intervalsLow every 5 years, moderate every 2 years, high annuallyLow 5 years, intermediate (untreated) 2 years, First Nations annually; high risk managed clinically rather than reassessed
Target after ACSLDL-C <1.8 mmol/LLDL-C <1.4 mmol/L and ≥50% reduction (2025 ACS guideline)
Ezetimibe on PBSAuthority (streamlined) with criteriaUnrestricted benefit for 30-day supply (from 1 Nov 2024)
PCSK9 optionsEvolocumab or alirocumabEvolocumab or inclisiran (alirocumab no longer available)
Where candidates lose marks

From the RACGP KFP 2025.1 public exam report17

  • CVD risk assessment case: many candidates missed that a low-risk patient did not need a statin, and that self-prescribing was inappropriate. Candidates who knew the updated calculator did well.
  • Ordering tests that are not indicated: thyroid function tests were a common error in that routine risk-assessment case. Check TSH when you find raised LDL-C or before treating it, not by reflex in every risk assessment.
  • Diabetes, lipids and microalbuminuria case: medication management was generally answered well; non-pharmacological management of retinopathy was harder for many candidates.

Other common traps

  • Using the old post-ACS target (<1.8 mmol/L) or forgetting the ≥50% reduction requirement.
  • Jumping to a PCSK9 inhibitor before ezetimibe has been added to a maximum statin.
  • Stopping statins for good after one episode of myalgia instead of withholding and rechallenging.
  • Starting a statin in a patient on dialysis.

12. Worked case (KFP style)

Michael, 38, a carpenter, attends after a workplace health check found a total cholesterol of 9.1 mmol/L. He feels well, does not smoke and drinks 6 standard drinks a week. His father had a myocardial infarction at 47 and died at 52. On examination there are nodular thickenings of both Achilles tendons. BMI is 26. Blood pressure is 128/80.

Question 1. What is the most likely diagnosis? (Write one answer.)

Show answer

Heterozygous familial hypercholesterolaemia. “Hypercholesterolaemia” alone or “dyslipidaemia” scores zero, because the key feature is the inherited, monogenic diagnosis that changes management for him and his family.

Question 2. List up to four blood or urine tests you would order to exclude secondary causes.

Show answer
  • TSH
  • LFTs (cholestasis)
  • UEC with eGFR, and urine albumin:creatinine ratio (CKD, nephrotic syndrome)
  • HbA1c or fasting glucose

A repeat (fasting) lipid profile is reasonable but does not exclude a secondary cause; more than four answers are not marked beyond the first four.

Secondary-cause tests are normal. A fasting lipid profile shows LDL-C 7.0 mmol/L, HDL-C 1.1 mmol/L and triglycerides 1.4 mmol/L.

Question 3. What is his Dutch Lipid Clinic Network score and category? (Write one answer.)

Show answer

12 — definite FH. Tendon xanthomas 6 + LDL-C 6.5–8.4 mmol/L 5 + first-degree relative with premature CHD 1 = 12 (>8). Only the highest-scoring item in each group counts.

Question 4. List up to four management steps you would take now.

Show answer
  • Start a high-intensity statin (e.g. rosuvastatin 20–40 mg or atorvastatin 40–80 mg); add ezetimibe if needed. Do not run the CVD risk calculator — he is clinically high risk.
  • Refer to a lipid clinic or specialist for confirmation and index-case genetic testing (MBS 73352 is specialist-requested).
  • Explain inheritance (50% risk to each child and sibling) and arrange screening of first-degree relatives, including his children from age 5–10; once a variant is found, the GP can order cascade testing (MBS 73353).
  • Lifestyle advice and recheck lipids, ALT and symptoms in 4–12 weeks.

“Recheck lipids in 6 months before treating” scores zero: definite FH is treated without waiting for lifestyle change.

13. Self-check questions

These questions are written at or above AKT difficulty. Every option is plausible and the options are deliberately similar. Commit to an answer before revealing the explanation.

⏱ Exam-pace challenge. The AKT gives you 4 hours for 150 questions — about 1.6 minutes each.19 Time yourself: Questions 1–5 in 8 minutes, then 6–10 in 8 minutes. Rate your confidence honestly before you reveal each answer.
Question 1

Robert Fielding, aged 63 years, was discharged six weeks ago after a non-ST-elevation myocardial infarction. His LDL-C on admission was 3.6 mmol/L. He takes atorvastatin 80 mg daily, aspirin, ticagrelor, metoprolol and ramipril, and says he has not missed a dose.

Today his LDL-C is 1.9 mmol/L* and triglycerides are 1.5 mmol/L. He has no muscle symptoms and his ALT is normal.

What is the MOST appropriate change to his lipid-lowering treatment?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: A. Add ezetimibe 10 mg to atorvastatin 80 mg

Feedback: This question requires candidates to apply the two-part post-ACS target. His LDL-C has fallen by 47%, short of the 50% reduction, and is above 1.4 mmol/L. He is already on a maximum high-intensity statin, so the next step is ezetimibe, which lowers LDL-C by about a further 20%.

  • Add fenofibrate 145 mg to atorvastatin 80 mg: his triglycerides are normal, and fibrates do not lower LDL-C enough or reduce events on top of a statin.
  • Add icosapent ethyl 4 g to atorvastatin 80 mg: PBS criteria require fasting TG 1.7–5.6 mmol/L with LDL-C already controlled; neither applies.
  • Start evolocumab with atorvastatin 80 mg: PBS-subsidised PCSK9 therapy requires LDL-C above target despite statin plus ezetimibe.
  • Switch atorvastatin 80 mg to rosuvastatin 40 mg: both are maximum high-intensity statins; switching adds little.

Reference: Heart Foundation and CSANZ. Australian clinical guideline for diagnosing and managing acute coronary syndromes, 2025.

Got this wrong? Re-read 4.2 Secondary prevention: treat everyone, treat to target →

Question 2

Priya Raman, aged 47 years, attends to discuss blood tests ordered for fatigue and weight gain. She does not smoke, has no family history of premature cardiovascular disease and has no xanthomas.

TestResultNormal range
Total cholesterol7.9*<5.5 mmol/L
LDL-C5.7*<3.5 mmol/L
TSH16.2*0.4–4.0 mU/L
Free T47*10–20 pmol/L

Her estimated 5-year CVD risk is 2%. What is the MOST appropriate next step?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: E. Start thyroxine, repeat lipids once she is euthyroid

Feedback: This question requires candidates to recognise a secondary cause before labelling primary hypercholesterolaemia. Overt hypothyroidism raises LDL-C, often into the FH range, and increases statin myopathy risk. Treat it and reassess the lipids when TSH has normalised.

  • Calculate DLCN score, start rosuvastatin 10 mg: DLCN uses untreated LDL-C without secondary causes; her LDL-C is not interpretable yet.
  • Refer to a lipid clinic for FH genetic testing: MBS index testing requires LDL-C without a secondary cause.
  • Repeat her CVD risk assessment in five years: TC >7.5 mmol/L cannot be left for five years; the cause must be addressed now.
  • Start atorvastatin 20 mg, repeat lipids in 6 weeks: treats the number but not the cause, with higher myopathy risk while hypothyroid.

Reference: Therapeutic Guidelines. Cardiovascular: lipid modification (current version).

Got this wrong? Re-read 2.1 Primary and secondary dyslipidaemia →

Question 3

Tony Marsh, aged 66 years, had a myocardial infarction two years ago. Three weeks after his atorvastatin was increased from 40 mg to 80 mg, he developed aching in both thighs that is stopping him from walking his dog. He has no weakness and his urine is normal in colour.

CK is 380 U/L* (normal <200 U/L). TSH, creatinine and vitamin D are normal. He takes no other new medicines. LDL-C before the dose increase was 1.7 mmol/L.

What is the MOST appropriate management?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: E. Withhold atorvastatin, rechallenge at 40 mg once settled

Feedback: This question requires candidates to manage intolerable statin myalgia without abandoning statin therapy in secondary prevention. CK is under 5 × ULN and there are no features of rhabdomyolysis, but the symptoms are limiting. Withhold for 2–4 weeks until settled, then rechallenge at the previously tolerated dose and add ezetimibe if needed to reach target.

  • Continue atorvastatin 80 mg and recheck CK in 4 weeks: appropriate only if symptoms were tolerable; his are limiting his activity.
  • Stop atorvastatin and start ezetimibe 10 mg alone: abandons the statin after one episode; ezetimibe alone will not reach his target.
  • Stop atorvastatin and start evolocumab fortnightly: PBS criteria require statin intolerance to be established and ezetimibe tried first.
  • Stop atorvastatin, add coenzyme Q10 and rechallenge: coenzyme Q10 has not been shown to prevent statin muscle symptoms.

Reference: Therapeutic Guidelines. Cardiovascular: statin-associated muscle symptoms (current version).

Got this wrong? Re-read 7. Statin safety and muscle symptoms →

Question 4

Daniel Kovac, aged 52 years, has type 2 diabetes with an HbA1c of 10.4%*. He drinks about 40 standard drinks a week. He has no abdominal pain and no history of pancreatitis.

A fasting lipid profile shows triglycerides 14.6 mmol/L*, total cholesterol 8.2 mmol/L* and HDL-C 0.7 mmol/L*. LDL-C could not be calculated. His eGFR is 78 mL/min/1.73m².

What is the MOST appropriate initial management?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: C. Add fenofibrate 145 mg, stop alcohol, improve glucose

Feedback: This question requires candidates to prioritise pancreatitis prevention when fasting triglycerides exceed 10 mmol/L. Alcohol abstinence and glycaemic control are essential, and a fibrate is the drug that lowers triglycerides fastest. Statin therapy for his overall CVD risk is added once triglycerides fall.

  • Add atorvastatin 40 mg, stop alcohol, improve glucose: statins lower triglycerides only modestly and do not address the immediate pancreatitis risk.
  • Add gemfibrozil 600 mg, stop alcohol, improve glucose: fenofibrate is preferred because a statin will be needed and gemfibrozil cannot be combined with one.
  • Add icosapent ethyl 2 g, stop alcohol, improve glucose: PBS criteria require established CVD and TG 1.7–5.6 mmol/L.
  • Add colestyramine 4 g, stop alcohol, improve glucose: bile acid sequestrants raise triglycerides.

Reference: Therapeutic Guidelines. Cardiovascular: hypertriglyceridaemia (current version).

Got this wrong? Re-read 9. Hypertriglyceridaemia and low HDL →

Question 5

Hannah Brooks, aged 33 years, has genetically confirmed heterozygous familial hypercholesterolaemia. She takes rosuvastatin 20 mg and ezetimibe 10 mg daily, with an LDL-C of 2.4 mmol/L. She has no cardiovascular disease and normal coronary imaging.

She wishes to start trying to conceive in the next three months.

What is the MOST appropriate advice about her lipid-lowering treatment?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: B. Stop both medicines now, consider colestyramine

Feedback: This question requires candidates to give pre-conception advice for FH. Statins (TGA category D) and ezetimibe should be stopped before conception, usually 1–3 months beforehand. A few months off treatment adds little to lifetime risk in someone without ASCVD. Colestyramine is not absorbed and can be used if LDL-C lowering is needed.

  • Continue both medicines until a positive pregnancy test: exposes the embryo during organogenesis; stopping should be planned.
  • Stop rosuvastatin now and continue ezetimibe alone: ezetimibe is also avoided in pregnancy because of limited safety data.
  • Switch both medicines to evolocumab fortnightly: monoclonal antibodies cross the placenta and are not recommended in pregnancy.
  • Switch rosuvastatin to pravastatin 40 mg now: pravastatin is still a statin and is not the standard pre-conception choice.

Reference: Therapeutic Guidelines. Cardiovascular: lipid modification in pregnancy (current version); Australian Medicines Handbook 2026.

Got this wrong? Re-read 10. Special populations →

Question 6

Gwen Talbot, aged 76 years, takes atorvastatin 20 mg daily for primary prevention and has done so for nine years without problems. She plays two rounds of golf a week and has no muscle aches or weakness.

A specialist who saw her for knee osteoarthritis ordered a CK, which was 310 U/L* (normal <200 U/L). Her LDL-C is 2.3 mmol/L, TSH and creatinine are normal.

What is the MOST appropriate management?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: B. Continue atorvastatin with no further CK testing

Feedback: This question requires candidates to show restraint with an incidental, asymptomatic CK rise. Her CK is under 2 × ULN, she has no symptoms, and exercise readily explains it. Routine CK monitoring is not recommended, and no change to an effective, well-tolerated statin is needed.

  • Continue atorvastatin and repeat CK in two weeks: repeat testing in an asymptomatic person with CK <4–5 × ULN adds nothing.
  • Halve atorvastatin dose and repeat CK in a month: reduces benefit for a laboratory finding without clinical significance.
  • Stop atorvastatin, repeat CK in four weeks: stopping is reserved for intolerable symptoms or CK >5 × ULN with symptoms.
  • Switch atorvastatin to pravastatin 40 mg daily: switching is for intolerance, which she does not have.

Reference: Therapeutic Guidelines. Cardiovascular: monitoring statin therapy (current version).

Got this wrong? Re-read 7. Statin safety and muscle symptoms →

Question 7

Samuel Okoro, aged 67 years, has been on haemodialysis for 18 months for diabetic kidney disease. He has never had a cardiovascular event and has no symptoms of angina or claudication. He is not taking a statin.

His LDL-C is 3.4 mmol/L and triglycerides are 2.6 mmol/L. He asks whether he should start a cholesterol tablet.

What is the MOST appropriate advice?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: A. Do not start a statin, as benefit on dialysis is unproven

Feedback: This question requires candidates to apply the dialysis exception. Statins reduce events in CKD not on dialysis, but trials in people already on dialysis (4D, AURORA, and the dialysis subgroup of SHARP) showed no significant benefit. Statins are not started in dialysis patients without another indication, although they are continued if already taken.

  • Start atorvastatin 40 mg, as CKD makes his risk high: true for CKD before dialysis, not for starting treatment on dialysis.
  • Start fenofibrate 145 mg, as his triglycerides are high: his TG is only mildly raised, and fenofibrate is avoided in severe kidney impairment.
  • Start rosuvastatin 20 mg, as dialysis makes his risk high: AURORA tested rosuvastatin in dialysis and found no benefit; 20 mg also exceeds the dose for severe kidney impairment.
  • Start simvastatin with ezetimibe, as used in SHARP: the benefit in SHARP came from people not yet on dialysis.

Reference: Kidney Health Australia. Chronic kidney disease management in primary care, 5th edition, 2020.

Got this wrong? Re-read 10. Special populations →

Question 8

Peter Lindqvist, aged 61 years, had a coronary stent two years ago and has type 2 diabetes with persistent microalbuminuria. For the past four months he has taken atorvastatin 80 mg and ezetimibe 10 mg daily with confirmed adherence, alongside dietary changes and regular walking.

His LDL-C is 2.2 mmol/L*. He has no muscle symptoms and his ALT is normal.

What is the MOST appropriate next step?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: D. Apply for PBS-subsidised evolocumab

Feedback: This question requires candidates to recognise PBS eligibility for PCSK9-directed therapy. He has symptomatic ASCVD, an LDL-C above 1.8 mmol/L despite maximum statin plus ezetimibe with diet and exercise, and an additional high-risk feature (diabetes with microalbuminuria). Evolocumab lowers LDL-C by about 50–60% further and reduces events.

  • Add colestyramine 4 g twice daily: gives a small LDL-C fall with poor tolerability; it will not reach target.
  • Add fenofibrate 145 mg once daily: fibrates do not lower LDL-C enough or reduce events on a statin.
  • Add icosapent ethyl 2 g twice daily: PBS criteria require LDL-C 1.0–2.6 and TG 1.7–5.6 mmol/L; his TG is not given as raised, and LDL-C is the priority.
  • Switch to rosuvastatin 40 mg daily: he is already on a maximum high-intensity statin.

Reference: Pharmaceutical Benefits Scheme. Evolocumab restriction (current Schedule); Pham and Brieger, MedicineToday 2025.

Got this wrong? Re-read 6.3 PCSK9-directed therapy →

Question 9

Marcus Hale, aged 44 years, had an ST-elevation myocardial infarction three months ago. He has never smoked, does not have diabetes, has a BMI of 24 and his blood pressure was normal before the event. His LDL-C on admission was 2.9 mmol/L.

His mother had a stroke at 56 and his maternal uncle a myocardial infarction at 49. He asks why this happened to him.

Which additional test is MOST appropriate to explain his premature event?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: D. Lipoprotein(a) concentration

Feedback: This question requires candidates to identify the inherited risk factor that a standard lipid profile misses. Lp(a) is genetically determined, causal, unaffected by statins and recommended once in people with premature ASCVD and a family history of premature disease. A high level supports more intensive LDL-C lowering and testing of relatives. Testing is not Medicare-funded.

  • Apolipoprotein B concentration: adds little when LDL-C and TG are known and normal; it does not detect Lp(a) excess specifically.
  • Coronary artery calcium score: a primary prevention tool; he already has established coronary disease.
  • High-sensitivity CRP level: not recommended for risk assessment in Australian guidance and does not change management.
  • Plasma homocysteine level: lowering homocysteine has not reduced events; testing is not recommended.

Reference: Ward NC, Watts GF, et al. Australian Atherosclerosis Society position statement on lipoprotein(a). Heart Lung Circ 2023.

Got this wrong? Re-read 3.4 Lipoprotein(a) and other tests →

Question 10

Lucy Tran, aged 45 years, presents with three weeks of puffy eyes, tiredness and 4 kg of weight gain. She has pitting oedema to the mid-shins. Her blood pressure is 142/88 mmHg.

TestResultNormal range
Total cholesterol10.2*<5.5 mmol/L
LDL-C7.4*<3.5 mmol/L
Albumin21*35–50 g/L
TSH2.10.4–4.0 mU/L
ALP, bilirubinNormal—

Her lipid profile two years ago was normal. What is the MOST likely cause of her hypercholesterolaemia?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: G. Primary nephrotic syndrome

Feedback: This question requires candidates to identify a secondary cause that mimics hypothyroidism. New, marked hypercholesterolaemia with oedema, periorbital puffiness and an albumin of 21 g/L points to nephrotic syndrome: low oncotic pressure drives hepatic lipoprotein synthesis. The next test is a urine albumin:creatinine ratio.

  • Cholestatic liver disease: excluded by normal ALP and bilirubin.
  • Familial hypercholesterolaemia: lifelong; excluded by a normal profile two years ago.
  • Iatrogenic Cushing syndrome: she takes no corticosteroids and has no Cushingoid features; it would not explain an albumin of 21 g/L.
  • Polygenic hypercholesterolaemia: also lifelong, so it cannot explain a new rise within two years.
  • Autoimmune hypothyroidism: the obvious mimic, but TSH is normal.
  • Primary biliary cholangitis: a cholestatic disease with raised ALP.
  • Type 2 diabetes mellitus: raises triglycerides more than LDL-C and does not cause hypoalbuminaemia.

Reference: Therapeutic Guidelines. Cardiovascular: secondary causes of dyslipidaemia (current version).

Got this wrong? Re-read 2.1 Primary and secondary dyslipidaemia →

Self-check score: / 10

Sure but wrong:

Any “sure but wrong” answer is your highest exam risk. Re-read those sections first, then use the flashcards below. Your selections are not saved; the score resets when you leave the page.

Exam-readiness check

Tick each one you can do without notes. Anything left unticked is your revision list.

Ready on of 9.

14. Key takeaways

Remember for the exam
  • Primary prevention: treat by absolute risk (high ≥10% prescribe; intermediate consider; low not routinely, unless TC >7.5).
  • Secondary prevention: high-intensity statin for all with ASCVD. After ACS: LDL-C <1.4 mmol/L and ≥50% reduction.
  • Exclude secondary causes first: TSH, HbA1c, UEC/eGFR, uACR, LFTs, medicines, alcohol.
  • Non-fasting lipids are fine for most purposes; use non-HDL-C when TG are raised. Fast if TG >4.5.
  • Step-up: high-intensity statin → add ezetimibe (unrestricted PBS since Nov 2024) → PCSK9-directed therapy if PBS criteria met.
  • SAMS: CK <5 × ULN and tolerable → continue; intolerable → withhold 2–4 weeks and rechallenge; weakness or CK >10 × ULN → assess for rhabdomyolysis. No routine CK testing.
  • Interactions: simvastatin/atorvastatin with CYP3A4 inhibitors; never gemfibrozil with a statin; stop statin with systemic fusidic acid.
  • FH: 1 in 250; suspect if LDL-C ≥5.0; DLCN definite >8, probable 6–8. Index genetic test by specialist (MBS 73352); GP can order cascade testing (MBS 73353).
  • TG >10 mmol/L: pancreatitis risk — alcohol abstinence, glucose control, fenofibrate.
  • Lp(a): test once in premature ASCVD or FH; not Medicare-funded.
  • Pregnancy: stop statins and ezetimibe before conception; colestyramine if needed.
  • Dialysis: do not start a statin; continue if already taking one.

Your revision plan

Spaced revision for this lesson
WhenWhat to do
TodayFinish the lesson, both question sets and the readiness checklist. Note every “sure but wrong” answer.
Day 3Do this lesson’s 10 flashcards again (end of this lesson). Re-read every section you marked “Not yet”.
Day 7Redo the self-check questions without looking at the lesson. Aim for 8/10 with no “sure but wrong”.
Day 21Do the cardiovascular chapter flashcard deck, then one timed block of mixed cardiovascular questions at exam pace.
Week before the examRe-read the key takeaways and the old-notes box. Do the chapter flashcard deck once more.

Your next step

Use your scores from the cold-start check and the self-check questions to choose your next step.

Self-check under 6/10, or any “sure but wrong”: your knowledge has gaps you may not have noticed. Start the flashcards for this lesson today and re-read the sections you missed.This lesson’s 10 flashcards
6–8/10: the knowledge is there but not yet secure. Do the flashcards daily for a week, then redo the self-check.Start the flashcards
9–10/10 with no confident errors: move on to the next lesson and keep this topic fresh with the full cardiovascular deck once a week.Cardiovascular chapter deck

Flashcards: 10 high-yield recall cards

Finish the lesson by testing your recall. Say the answer out loud before you tap the card to flip it, then mark “I knew this” only if you were fully right without looking. Repeat the cards on day 3 and day 21, and use the cardiovascular chapter deck for later reviews.

Card 1 of 10 · Section 4.2

← Previous

Card 2 of 10 · Section 6.1

Card 3 of 10 · Section 6.1

Card 4 of 10 · Section 6.2

Card 5 of 10 · Section 6.3

Card 6 of 10 · Section 7

Card 7 of 10 · Section 7

Card 8 of 10 · Section 8

Card 9 of 10 · Section 9

Card 10 of 10 · Section 10

Knew it: / 10 known

15. References and recommended reading

References

  1. Commonwealth of Australia, Department of Health and Aged Care. Australian guideline for assessing and managing cardiovascular disease risk. Canberra; 2023. cvdcheck.org.au (accessed 10 Nov 2026).
  2. Nelson MR, et al. 2023 Australian guideline for assessing and managing cardiovascular disease risk. Med J Aust 2024;220(9):482–90.
  3. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Australian clinical guideline for diagnosing and managing acute coronary syndromes 2025. heartfoundation.org.au (accessed 10 Nov 2026).
  4. Pham A, Brieger D. Lipid-lowering therapy after acute coronary syndrome: new developments. MedicineToday 2025;26(7):23–6. And: Chetty, Lan, Watts. Advances in lipid management. MedicineToday 2025;26(5):37–41.
  5. Therapeutic Guidelines. Cardiovascular (current version, eTG complete). Melbourne: Therapeutic Guidelines Ltd.
  6. Pharmaceutical Benefits Scheme. PBS restrictions for ezetimibe and its fixed dose combinations (changes from 1 November 2024). pbs.gov.au (accessed 10 Nov 2026).
  7. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice (the Red Book). 10th edn. Melbourne: RACGP; 2024.
  8. Pharmaceutical Benefits Scheme. Medicine status: bempedoic acid; bempedoic acid with ezetimibe (PBAC July 2026: not recommended). pbs.gov.au (accessed 10 Nov 2026).
  9. Stroke Foundation. Living clinical guidelines for stroke management: secondary prevention. Melbourne; current version. informme.org.au
  10. Birkenhead K, et al. Familial hypercholesterolaemia: improving the health of individuals and families. MedicineToday 2024;25(6 Suppl):15–20. And: Watts GF, et al. Consensus guidance for FH (FH Australasia Network). Heart Lung Circ 2021.
  11. Ward NC, Watts GF, et al. Australian Atherosclerosis Society position statement on lipoprotein(a): clinical and implementation recommendations. Heart Lung Circ 2023;32(3):287–96.
  12. newsGP. Heart health risk hidden without routine testing (lipoprotein(a)). 21 Aug 2025. racgp.org.au (accessed 10 Nov 2026).
  13. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–81.
  14. Australian Medicines Handbook 2026. Adelaide: AMH Pty Ltd; 2026 (statins, ezetimibe, fibrates, PCSK9 inhibitors).
  15. Pharmaceutical Benefits Scheme. Evolocumab and inclisiran restrictions (current Schedule); PBAC Public Summary Documents, evolocumab March 2024 and inclisiran November 2024. pbs.gov.au
  16. NACCHO and RACGP. National guide to preventive healthcare for Aboriginal and Torres Strait Islander people. 4th edn. Melbourne: RACGP; 2024.
  17. The Royal Australian College of General Practitioners. KFP 2025.1 public exam report. Melbourne: RACGP; 2025. racgp.org.au (accessed 10 Nov 2026).
  18. The Royal Australian College of General Practitioners. AKT 2026.2 public exam report. Melbourne: RACGP; 2026. racgp.org.au (accessed 10 Nov 2026).
  19. The Royal Australian College of General Practitioners. AKT and KFP: general exam delivery information. racgp.org.au (accessed 10 Nov 2026).

Recommended reading for RACGP fellowship candidates

  • Therapeutic Guidelines: Cardiovascular (lipid modification) and the Australian Medicines Handbook — drug choice, doses, interactions and SAMS.
  • Aus CVD Risk Calculator and 2023 guideline — cvdcheck.org.au.
  • 2025 Heart Foundation/CSANZ ACS guideline — secondary prevention lipid targets.
  • PBS Schedule — read the current restrictions for ezetimibe, evolocumab, inclisiran and icosapent ethyl.
  • FH Australasia Network consensus guidance and the Australian Atherosclerosis Society Lp(a) statement.
  • RACGP Red Book (10th edn) and the National guide (NACCHO/RACGP) — screening.
  • RACGP check units on cardiovascular prevention and Australian Journal of General Practice articles on FH and cascade testing.
  • Australian Prescriber — reviews of statin intolerance and PCSK9 inhibitors.
  • Murtagh’s General Practice, 8th edition — dyslipidaemia chapter.

Version history

VersionDateChanges
2026–27 (v1.3)10 Nov 2026Study-priority stars (1–4) added to every section and subsection, with a star key and a “short on time” fast path to the must-know sections. Flashcards moved to the end of the lesson and shown on the page (no pop-up). Edition and date labels removed from the trainee view.
2026–27 (v1.2)10 Nov 2026Added 10-card flashcard pop-up; next-step buttons now open the flashcards and link to the cardiovascular chapter deck.
2026–27 (v1.1)10 Nov 2026Engagement layer added: cold-start check, old-notes check, exam-report pitfalls, selectable questions with confidence rating and score, exam-pace challenge, readiness checklist, revision plan and flashcard links.
2026–27 (v1.0)10 Nov 2026First edition. Based on 2023 CVD risk guideline, 2025 ACS guideline, PBS changes (ezetimibe Nov 2024; inclisiran Apr 2024; icosapent ethyl Oct 2024), PBAC bempedoic acid decision (Jul 2026), AAS Lp(a) statement.

© GP Institute of Australia. For educational use by enrolled candidates only; not for redistribution. This lesson summarises Australian guidelines for exam preparation and does not replace current clinical guidelines or clinical judgement. Always check doses and PBS restrictions in current Therapeutic Guidelines, AMH and the PBS Schedule.

Sorry, You cannot copy contents of this page.

If you are trying to login, please use the right click to enter you details!

Scroll to Top